Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Logo for

Science 331 (6024): 1612-1616

Copyright © 2011 by the American Association for the Advancement of Science

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

Gregory L. Beatty1,2,6, Elena G. Chiorean3, Matthew P. Fishman1, Babak Saboury5, Ursina R. Teitelbaum2,6, Weijing Sun2,6, Richard D. Huhn4, Wenru Song4, Dongguang Li4, Leslie L. Sharp4, Drew A. Torigian2,5, Peter J. O’Dwyer2,6, and Robert H. Vonderheide1,2,6,*

1 Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, 421 Curie Boulevard, Philadelphia, PA 19104, USA.
2 Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
3 Division of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
4 Pfizer Corporation, New London, CT 06320, USA.
5 Department of Radiology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
6 Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.


Figure 1
View larger version (44K):
[in this window]
[in a new window]

 
Fig. 1. Agonist CD40 mAb in combination with gemcitabine induces clinical responses in patients with surgically incurable PDA. (A) Best overall percentage of change from baseline in tumor target lesion measurement shown as a waterfall plot. *Patient 10061001 was defined as PD because of the appearance of a new nontarget lesion. **Patient 10031001 did not obtain posttherapy scans because of clinical deterioration from disease progression after one dose of CP-870,893. ***Patient 10031010 came off the study after one dose of CP-870,893 but restarted gemcitabine alone and achieved a PR. (B) CT imaging obtained at baseline and end of cycle 3. The primary pancreatic tumor and two metastatic liver lesions are marked by arrows, with the longest dimension annotated. (C) Histopathology of a biopsied metastatic lesion [from patient 10031016 (left)] and a surgically resected primary pancreatic lesion [from patient 10061003 (right)]. Both patients achieved a PR. Patient 10031016 underwent tumor biopsy after completing four cycles of therapy; patient 10061003 underwent surgical resection of the primary tumor after 12 cycles of therapy. Arrows (left) indicate a macrophage-dominated inflammatory infiltrate within extensive tumor necrosis. Arrows (right) identify polymorphonuclear infiltrating cells without lymphocytes; arrowheads mark tumor cells. Scale bars, 50 μm.

 

Figure 2
View larger version (37K):
[in this window]
[in a new window]

 
Fig. 2. Antitumor activity of agonist CD40 mAb in KPC mice is T cell–independent. (A) KPC mice were treated with gemcitabine or phosphate-buffered saline (PBS) on day 0 and day 7, with control IgG2a or FGK45 administered on day 2. Cohorts of KPC mice receiving treatment with FGK45 were also depleted of CD4+ or CD8+ cells or both CD4+ and CD8+ cells with the use of GK1.5 and 2.43 antibodies, respectively, on days –1, 0, 1, 3, 7, and 10. Percent change in tumor volume from day –1 (baseline) to day +14 is shown for each mouse as a waterfall plot (in comparison with PBS + IgG2a, gemcitabine + FGK45: P < 0.05; gemcitabine + IgG2a: P = 1.00; PBS + FGK45: P < 0.05; FGK45 + GK1.5: P < 0.05; FGK + 2.43: P < 0.05; FGK45 + GK1.5 + 2.43: P < 0.05; Fisher’s exact test). Hematoxylin and eosin (H&E) histology [(B) to (E)] and CD3 immunohistochemistry [(F) to (I)] are shown for tumors from KPC mice treated with IgG2a (B and F) or FGK45 (C to E and G to I). Responders (D), (E), (H), and (I) were defined as FGK45-treated mice that demonstrated tumor regression by ultrasound analysis. FGK45-treated mice with tumor progression by ultrasound were defined as nonresponders (C) and (G). Scale bars, 50 μm.

 

Figure 3
View larger version (58K):
[in this window]
[in a new window]

 
Fig. 3. Agonist CD40 mAb targets systemic macrophages before their infiltration of tumor. Immunohistochemistry was used to quantify leukocyte infiltration (A) into peripancreatic lymph nodes (A, B, and F) and KPC tumor (A, C, D, E, and G) by staining with a biotinylated goat antibody directed against rat IgG to detect FGK45 or RB6-8C5 bound to cells at 10 min (A) to (D) or 18 hours (A) and (E) to (G) after treatment. Macrophages were depleted with CELs before FGK45 treatment (A) and (G). LN, peripancreatic lymph node; T, tumor; scale bars, 50 μm. Error bars in (A) represent SD. (H) A heat map displaying the flow cytometric analysis of tumor-associated macrophages from individual KPC mice (columns) for expression of cell surface molecules (rows) 3 days after treatment with control IgG2a compared with FGK45. (Top) The percentage of tumor-associated macrophages with surface molecule expression. (Bottom) Mean fluorescence intensity as the number of standard deviations from the mean, which was determined from treatment with control IgG2a. P values are based on Student’s t test; nd, not determined.

 

Figure 4
View larger version (72K):
[in this window]
[in a new window]

 
Fig. 4. CD40 activated tumor-infiltrating macrophages mediate tumor regression. (A) KPC mice were treated with control IgG2a or FGK45 or FGK45 plus depletion of systemic macrophages by means of CELs. Shown is a waterfall plot displaying percent change in tumor volume from baseline to day +14 (in comparison with IgG2a, FGK45: P < 0.05; FGK45 + CELs: P = 1.00; Fisher’s exact test). (B) F4/80+ tumor-associated macrophages were isolated from KPC mice that had been treated with FGK45 (blue squares) or control IgG2a (green circles) and incubated with KPC-derived tumor cell lines. Tumor cell death in vitro was measured by 7-aminoactinomycin D (7-AAD) labeling and flow cytometric analysis at 24 hours. Shown is a representative assay from two independent experiments each performed in triplicate. Means ± SD are depicted; *P < 0.05, Student’s t test. (C) Cleaved caspase 3 expression on KPC tumors was determined by immunohistochemistry 18 hours after treatment with control IgG2a (top panel) or FGK45 (bottom panel). (D) to (L) KPC tumors were analyzed 18 hours after treatment with control IgG2a (D, F, and H), FGK45 (E, G, and I), or FGK45 + CEL (J, K, and L). Shown are hematoxylin-and-eosin histology (D, E, J); Masson’s trichrome stain to reveal extracellular matrix in blue [(F), (G), and (K)], and immunohistochemistry for collagen I [(H), (I), and (L)]. Scale bars, 50 μm.

 


To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882